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Available online 28 December 2016Lipopolyamines (LPAs) are cationic lipids; they interact spontaneouslywith nucleic acids to form lipoplexes used
for gene delivery. The main hurdle to using lipoplexes in gene therapy lies in their immunostimulatory proper-
ties, so far attributed to the nucleic acid cargo, while cationic lipids were considered as inert to the immune sys-
tem. Here we demonstrate for the ﬁrst time that di-C18 LPAs trigger pro-inﬂammatory responses through Toll-
like receptor 2 (TLR2) activation, and this whether they are bound to nucleic acids or not. Molecular docking ex-
periments suggest potential TLR2 binding modes reminiscent of bacterial lipopeptide sensing. The di-C18 LPAs
share the ability of burying their lipid chains in the hydrophobic cavity of TLR2 and, in some cases, TLR1, at the
vicinity of the dimerization interface; the cationic headgroups form multiple hydrogen bonds, thus crosslinking
TLRs into functional complexes. Unravelling the molecular basis of TLR1 and TLR6-driven heterodimerization
upon LPA binding underlines the highly collaborative and promiscuous ligand binding mechanism. The preva-
lence of non-speciﬁcmain chain-mediated interactions demonstrates that potentially any saturated LPA current-
ly used or proposed as transfection agent is likely to activate TLR2 during transfection. Hence our study
emphasizes the urgent need to test the inﬂammatory properties of transfection agents and proposes the use of
docking analysis as a preliminary screening tool for the synthesis of new non-immunostimulatory nanocarriers.zuto), m
. This i© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Gene therapy1. Introduction
Gene therapy, a technique that aims to replace a defective ormissing
gene with its normal allele at its natural location, emerged in the 70's
[1], with the ﬁrst successful somatic treatment to leave permanent
DNA modiﬁcation performed in the 90's. Nonetheless the technique is
still in its infancy, and remains experimental in treating most diseases
that can be traced back to gene disorders. Recently, the European Com-
mission has approved treatment for adult patients diagnosed with fa-
milial lipoprotein lipase deﬁciency (LPLD) and for children with
severe combined immunodeﬁciency due to adenosine deaminase deﬁ-
ciency (ADA-SCID) [2–4].g308@cam.ac.uk
s an open access article underThe success of gene therapy is conditioned by the development of
vectors able to transfect cells efﬁciently with minimal adverse effects
[5–9]. Themostwidespread technique of transfection involves viral vec-
tors [10,11]. Viral vectors exhibit a high efﬁciency of transfection, but
because of their inherent immunogenicity, the risk of gene transmission
and/or recombination with germline cells, the limited space for foreign
therapeutic genes and the important limitations with respect to scale-
up procedures and costs, synthetic alternatives have been proposed [7,
12–15].
Among available synthetic vectors, cationic lipids, introduced by
Felgner in 1987 [16], have been widely studied and commonly used as
a result of their relatively high effectiveness, ease of production, lower
toxicity and immunogenicity and the possibility to confer tissue speci-
ﬁcity [14,17–21]. Nevertheless, it was further demonstrated that trans-
fection with cationic lipids/nucleic acids complexes, called lipoplexes,
causes inﬂammatory responses in vitro and in vivo [22–25]. In the last
decade it became apparent that delivery of foreign nucleic acids usingthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tors (PRRs) located in the endosomal compartment and cytosol with a
signiﬁcant risk of triggering a dangerous immune response and decreas-
ing the transfection efﬁciency [8,26]. In particular several endosomal
Toll-like receptors (TLRs) are dedicated to nucleic acid recognition:
TLR9 recognizes unmethylated CpG motifs of plasmid DNA (pDNA)
[27–30] and TLR7/8 and TLR3 recognize single (ssRNA) and double
stranded (dsRNA) RNA, respectively [31,32]. TLR engagement by nucleic
acids activates a signalling cascade leading to translocation of the nucle-
ar factor -κB (NF- κB) into the nucleus, followed by transcription and
production of several pro-inﬂammatory cytokines such as Tumor Ne-
crosis Factor α (TNF-α), Interleukin 6 and 12 (IL-6 and IL-12), which
were all reported after administration of lipoplexes [22,23,25].
Despite these cytokines being shared by multiple signalling path-
ways [33,34] the immuno-stimulatory properties of lipoplexes were
generally attributed to activation of TLR3, TLR7/8 and TLR9 by foreign
nucleic acids [22,23,35]. New approaches to minimize nucleic acid-de-
pendent immune responses were developed. Among them, minicircle
DNA, in which bacterial sequences required for production in bacteria
but not for gene expression have been removed [36,37], and CpG-free
technologies, that avoid TLR9 activation by using pDNA completely de-
void of unmethylated CpG [38], are the most advanced methods. Also
several RNA chemical modiﬁcations were performed to avoid interac-
tion with PRRs and prevent activation of an immune response [39]. De-
spite all these efforts, the results were not as successful as expected:
although preventing nucleic acids from triggering an immune response
does contribute to reducing the inﬂammation associated with
lipoplexes, cytokine secretion has not been eliminated [40–44]. This
suggests that there are othermechanisms responsible for the innate im-
mune responses of lipoplexes, which might be linked to their second
component, the cationic lipids.
Cationic lipid nanocarriers were typically considered as inert to the
immune system. Recent studies have shown that they are instead in-
volved in several cell-signalling mechanisms either with inﬂammatory
or anti-inﬂammatory properties [45–49]. Because of the wide number
of structures and variety of cellular effectors that can be involved, the
number of cationic lipids that have been investigated so far in terms of
their immunostimulatory properties is quite limited [49]. Among cat-
ionic lipids, the number of lipopolyamines (LPAs) available is increasing
due to ease of synthesis, high transfection efﬁciency and low toxicity. In-
deed spreading the cationic charge with primary and secondary amines
improves interactionwith nucleic acid and reduces the toxicity associat-
ed with the localized cationic charge of tertiary amines and the ether
linkage, while the amide linker improves serum compatibility and bio-
degradability [50–55].
In this paper, we investigate the role of three LPAs (Fig. 1) on the in-
ﬂammatory processes induced during transfection with lipoplexes.
These cationic lipids were previously developed in the context of anFig. 1. Structures of cationic Lintracellular delivery program and successfully used as DNA and
siRNAdelivery vectors [56–61]. Our results demonstrate that they all ac-
tivate TLR2 and confer inﬂammatory properties to the corresponding
lipoplexes. We elucidated the structural parameters that cause TLR2
recognition and compared the LPAs mode of binding to known TLR2
ligands.2. Materials and methods
2.1. Reagents and cell lines
Human embryogenic kidney cells were purchased from the Ameri-
can Type Culture Collection (293 [HEK293] (ATCC® CRL1573™)) and
human acute monocytic leukemia cell line (THP1 ECACC 88081201)
were obtained from European Collection of Authenticated Cell Cultures.
RPMI 1640 (Roswell Park Memorial Institute) and DMEM (Dulbecco's
Modiﬁed Eagle's Medium) media, L-glutamine, sodium pyruvate, peni-
cillin and streptomycin were from Lonza. Phorbol 12-myristate 13-ace-
tate (PMA) was from Sigma Aldrich. Fetal bovine serum (FBS) from
South America was from Lonza and FBS from North America was pur-
chased from Sigma-Aldrich. Ultrapure standard lipopolysaccharide
(LPS) from E. coli 0111:B4, Pam3CSK4, and Pam2CSK4 were from
InvivoGen. Human TLR2, TLR1, TLR6 and TLR4 neutralizing antibody
were purchase from InvivoGen (Cat. Code pab-hstlr2, pab-hstlr1, pab-
hstlr6 and pab-hstlr4).2.2. Liposome preparation
RPR120525, RPR120535 and RPR128506 were synthesized as de-
scribed earlier [45] and stored as powder at−20 °C. Lipid ﬁlms were
formed by dissolving powder in chloroform, followed by solvent evapo-
ration under nitrogen stream and vacuumdrying overnight, and kept at
−20 °C. Liposomeswere freshly formed by resuspending lipidﬁlms into
ﬁltered Hepes 10 mM heated at 56 °C and sonicated for 5 min
(BioRuptor, Diagenode) before each experiment.2.3. Lipoplex preparation
The protocol used for lipoplex formation was one described earlier
for transfection experiment (6 nmol of cationic lipid per μg of nucleic
acids) [59–61]. Brieﬂy, small interfering RNA (MISSION® siRNAUniver-
sal Negative Control from SigmaAldrich Cat. N. SIC001) and plasmid
DNA (pcDNA3.1 from Invitrogen Cat. N. V79020) were suspended in
150 mM NaCl and mixed with an equivalent volume of liposomes,
then incubated for 20 min at room temperature.PAs tested in this study.
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HEK 293 cells were maintained in DMEM supplemented with 10%
heat-inactivated FBS from North America, 2 mM L-glutamine, 1 mM so-
dium pyruvate, 50 U/mL penicillin, 50 μg/mL streptomycin.
THP-1 cells were cultured in RPMI 1640 supplemented with 10%
heat-inactivated FBS from South America, 2 mM L-glutamine, 1 mM so-
dium pyruvate, 50 U/mL penicillin, 50 μg/mL streptomycin.
All cells were incubated at 37 °C in a 5% CO2 atmosphere and tested
for mycoplasma contamination on a regular basis. To avoid divergence
from the parent line, cell cultures were passaged up to 10 times.2.5. HEK293 cell transfection and stimulation
Cells were transfected as previously described [62]. Brieﬂy, cells
were seeded at 4 × 104 cells/mL in 96-well plates (200 μL/ well) and
transiently transfected 4 days later. Expression vectors containing a
NF-κB transcription reporter vector encoding ﬁreﬂy luciferase (10 ng/
well pNF-κB-luc from Clontech), and a constitutively active reporter
vector encoding Renilla luciferase (5 ng/well phRG-TK; Promega), to-
gether with empty vector (pcDNA3.1 from Invitrogen Cat. N. V79020)
and cDNA encoding human membrane CD14 (3 ng/well) and human
TLR2 (0.5 ng/well) or human TLR4/MD2 (3 ng/well) (kindly provided
by Prof. Clare Bryant, University of Cambridge) were mixed with jetPEI
(Polyplus transfection Cat.N. 101-10N) and incubatedwith cells accord-
ing to manufacturer's instructions. After 48 h, medium was replaced
with serum freemediumand cells were incubated for 1 h, cellswere ad-
ditionally washed with serum free medium, then directly incubated for
6 hwith tested cationic lipids or lipoplexes (in serum-freemedium), ul-
trapure LPS (100 ng/mL), Pam3CSK4 (30 ng/mL) or Pam2CSK4 (30 ng/
mL) (in complete medium). Cells were washed with PBS and then
lysedwith passive lysis buffer (Promega). Luciferase and Renilla activity
on cell lysates were quantiﬁed on a BioTek Synergy HT microplateFig. 2. Lipoplexes (A) and liposomes (B) lead to TNF-α secretion in human macrophages. Prim
serum free medium, then cell supernatants were collected and TNF-α was quantiﬁed
mean + standard deviation of three replicate values (n = 3) after subtraction of the secre
independent replicates.reader using home-made luciferase reagent (20 mM Tricine, 2.67 mM
MgSO4·7H2O, 0.265 mM (MgCO3)4Mg(OH)2·5H2O, 0.1 mM EDTA,
33.3 mM DTT, 530 μM ATP, 270 μM Acetyl Coenzyme A (Lithium salt),
470 μM luciferin (Biosynth), pH 7.8, diluted 2 times in water before
use) or coelenterazine (Biosynth) dissolved in ethanol at 1 mg/mL and
diluted 500 times in PBS before use as previously described [63]. Fireﬂy
and Renilla luciferase activity on cell lysates were normalized and data
were expressed as fold induction as compared to unstimulated
conditions.2.6. THP-1 cell stimulation
THP-1 cells were primed by resuspending them in fresh medium
containing 50 nM PMA and seeding them in 96-well plates at
3.5 × 106 cells/mL in 200 μL/well two days prior to stimulation. After
24 h of incubation with PMA, the medium was replaced with fresh one,
and cells were incubated overnight to further allow cell differentiation.
The day of stimulation, medium was replaced with serum free
medium and cells were incubated for 1 h, then washed with serum
free medium. When speciﬁed cells were incubated for 1 h in the
presence of antibodies blocking human TLR2, TLR1, TLR6 or TLR4,
at ﬁnal concentrations of 20 μg/mL in serum-free medium prior to
stimulation with liposomes (in serum-free medium), Pam2CSK4 or
Pam3CSK4 (15 or 30 ng/mL), or ultrapure LPS (100 ng/mL) (in com-
plete medium). Stimulation was carried out over 5 h.2.7. Cytokine assays
After stimulation, cell culture supernatants were collected and
assayed for human TNF-α, using DuoSet ELISA kits from R&D Systems,
according to manufacturer's instructions with a BioTek Synergy HT Mi-
croplate Readers.ed THP1 cells were incubated for 5 h with the indicate amount of cationic lipids (μM) in
using ELISA assay following manufacturer's instructions. Each bar represents the
tion measured in absence of stimulant. The experiment is representative of at least 3
Fig. 3. Liposomes (A) and lipoplexes (B) activate NF-κB through a mechanism dependent on TLR2. HEK 293 cells were transfected with plasmids encoding hTLR2 and hCD14 (black), or
hTLR4, hMD2andhCD14 (grey) togetherwith a luciferase reporter plasmid dependent onNF-κB activation. Twodays after transfection, cellswere incubated for 1 h in serum-freemedium,
washed and then incubated for 6 hwith serum freemedium alone (Ctrl, 0) or the indicate amount of liposomes or lipoplexes (μM, serum freemedium) or LPS (ng/mL, completemedium)
or Pam2/3CSK4 (μM, complete medium). Luciferase and Renilla were then quantiﬁed in cell lysate, normalized and reported here as fold induction as compared to control. Each bar
represents the mean + standard deviation of three replicate values (n= 3). The experiment is representative of at least 3 independent replicates.
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The crystal structure of TLR2/TLR6 bound to Pam2CSK4 is known for
mouse proteins (Protein Data Bank (PDB) code 3A79). A set of twenty
human homologymodelswere generated based on themouse structure
usingModeller software 9 version 10 [64]. Among these 20models, the
model with overall lowest discrete optimized protein energy (DOPE)
score was chosen for further characterization. The quality of the best
model was then compared to the mouse crystal structure at individual
amino acid levels with an additional DOPE energy proﬁle, smoothed
over a 15 residue window and normalized by the number of restraints
acting on each residue. The proﬁle was subsequently visualized in
Excel and revealed the adequacy of the model and the template. TheFig. 4. Lipoplex-induced TNF-α secretion is solely dependent on TLR2. Primed THP1 cells were i
mL ﬁnal concentration after addition of stimulants) antibodies blocking TLR2 (AbTLR2) or TLR4
RPR 120535, 120525 and 128506made lipoplexes (20 μM, serum freemedium) or LPS (100 ng/
collected and TNF-α quantiﬁed by ELISA. Data are expressed as percent of secretion as compare
Each bar represents the mean + standard deviation of three replicate values (n= 3). The expquality of the model was good due to the high sequence identity be-
tween mouse and human species (about 70% in the region of interest
corresponding to residues 33 to 482). As previously reported the
shape and size of the lipid binding domains in TLRs vary dramatically
between human and mouse [65]. In our TLR2/TLR6 model we estimate
that the volume of the pocket increases by approximately 1.6 times in
human compared to mouse using CastP software [66].
2.9. In silico construction of lipopolyamines
The atomic coordinates of RPR ligands were generated using Sybyl
software (Tripos). The geometry of the molecules were optimized
using the Powell minimization method with initial optimization basedncubated for 1 h in serum-freemedium, then 1 hwith orwithout (noAb) 40 μg/mL (20 μg/
(AbTLR4). Then cells were incubated for 5 h with serum free medium alone (Ctrl) or with
mL, complete medium) or Pam3CSK4 (30 ng/mL, completemedium). The supernatant was
d to condition without antibodies (no anti) for each stimulant after subtraction of control.
eriment is representative of at least 3 independent replicates.
Fig. 5. LPA-induced TNF-α secretion is mainly dependent on TLR2/TLR1 heterodimer.
Primed THP1 cells were incubated for 1 h in serum-free medium, then 1 h with or
without (no Ab) 40 μg/mL of antibodies blocking TLR2 (AbTLR2), TLR1 (AbTLR1) or
TLR6 (AbTLR6). Then cells were incubated for 5 h with RPR 120535, 120525,128506
(20 μM, serum free medium), Pam2CSK4 or Pam3CSK4 (15 ng/mL, complete medium).
The supernatant was collected and TNF-α quantiﬁed by ELISA. Data are expressed as
percent of secretion as compared to condition without antibodies (noAb) for each
stimulant. Each bar represents the mean + standard deviation of three replicate values
(n= 3). The experiment is representative of at least 3 independent replicates.
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imumof 100 cycles of iteration. Partial chargeswere computedbased on
the Gasteiger-Hückel chargemethod. Autodockwas used to convert the
ﬁle into PDBQT format, which contains the atomic coordinates, partial
charges and atom types of the molecule.
2.10. Molecular docking
The human crystal structure of TLR2 in complex with TLR1 (PDB
code 2Z7X) and its homology model in complex with TLR6 were used
for docking upon removal of the synthetic ligands bound to the proteinTable 1
Binding energies and polar interactions between ligands and TLR2 heterodimers. Conserved in
*Pam2CSK4 is bound to mouse proteins. All other models involve human proteins.
Binding mode Binding energy TLR2
Main c
RPR 120535 TLR2/1 Both chains in TLR2 −31.1 kcal/mol F325
F349
L350
One chain in each receptor −32.2 kcal/mol L324
F325
TLR2/6 −28.5 kcal/mol F325
Y326
L350
F349
RPR 128506 TLR2/1 Both chains in TLR2 −31.9 kcal/mol L324
F325
F349
L350
One chain in each receptor −31.4 kcal/mol D327
TLR2/6 −29.9 kcal/mol L324
RPR 120525 TLR2/1 Both chains in TLR2 −32.1 kcal/mol L324
F325
S346
One chain in each receptor −32.5 kcal/mol F325
TLR2/6 −31.7 kcal/mol G293
F325
Pam2CSK4* TLR2/6 −25.2 kcal/mol F325
D327
F349
Pam3CSK4 TLR2/1 −35.4 kcal/mol F349complexes. RPR molecules were docked into TLR2 heterodimers using
Autodock Vina [67]. The receptor was kept rigid, whereas the ligand
was allowed total ﬂexibility. The Autogrid parameters were computed
on an initial grid size of 40 × 40 × 50 Å3, with a spacing of 1 Å. The
grid was centered on the complex at x = +13.706; y = −23.174;
z =+3.332. The default optimization parameters were used for the it-
erated search in Vina, with the default value of 8 for exhaustiveness.
Flexible docking performed with LPAs generated a number of poses
ranked according to their binding energies. The ﬁrst 9 poses were
then resubmitted to rigid docking in order to compare the binding ener-
gy ofmolecules of different sizes. This extra stepwas found useful to cir-
cumvent the biased scoring function in Autodock Vina dependent on
the number of torsion angles. Docking poses were analysed and struc-
tural images were generated in PyMol (http://www.pymol.org) and
Chimera [68]. Detailed interactions were also analysed using LigPlot+
[69].3. Results
3.1. Lipoplexes induce lipopolyamine-dependent TNF-α secretion in human
macrophages
In order to investigate the role of cationic lipids in the inﬂam-
matory processes induced during transfection, we studied the
immunostimulatory properties of lipoplexes and liposomes
made with RPR 128506, 120535 and 120525 (Fig. 1), cationic
lipopolyamines (LPAs) successfully used as DNA and siRNA deliv-
ery vectors [56–61], whose polar head is constituted by polyamines
mimicking peptide backbones linked to aliphatic hydrocarbon
chains by an amide group. All three carry diC18:0 fully saturated ali-
phatic chains but differ in their cationic head group structure. RPR
128506 and 120535 are linear with one terminal primary amine and
three secondary amines. RPR 128506 contains a pentane linker region
between both its amide bonds, whereas RPR 120535 and 120525 haveteractions compared to known crystal structures are underlined.
TLR1 TLR6
hain Side chain Main chain Side chain Main chain Side chain
N294
S329
G313′
F312 Q316′
G313′ Q316′
D327
S329
Y326
G313′Q316′
L318′
F319′
N294 G313′ Q316′
Fig. 6.Docking poses of di-C18 lipopolyamines. Three bindingmodes are predicted: (A–C)binding to TLR2/TLR1 heterodimerwith one chain buriedper TLR pocket; (D–F)with both chains
buried into TLR2; (G–I) binding to TLR2/TLR6 heterodimer with both chains buried into TLR2. The cartoon representation of TLR complexes was generated by Chimera.
187M. Pizzuto et al. / Journal of Controlled Release 247 (2017) 182–193a methane group instead. RPR 120525 is branched at N11′ and N16′,
thus bearing three terminal amines and two tertiary ones.
In order to characterize the inﬂammatory reaction induced by
lipoplexes and to investigate the involvement of LPAs rather than
nucleic acids we measured TNF-α secretion in primed THP-1 cells (a
monocytic cell line that expresses the whole repertoire of TLRs), after
incubation with increasing amounts of RPR 120535, 120525 or 128506
bound to nucleic acids (lipoplexes) or not (liposomes). As shown in
Fig. 2, lipoplexes made from RPR 120535, 120525 and 128506 induceFig. 7. LPA binding modes are reminiscent of bacterial lipopeptide recognition. (A) Superpositi
lipopeptide Cys-Ser-Lys4 (Pam3CSK4) bound tohumanTLR2/TLR1 (not shown). (B) Superpositio
bound to mouse TLR2/TLR6 (not shown). This ﬁgure has been generated in PyMol using alignea dose-dependent production of TNF-α cytokine and this increased in
the absence of nucleic acids cargo.
3.2. TLR2 activation by lipopolyamines is responsible for lipoplex-induced
TNF-α secretion
In order to identify the receptor responsible for the
immunostimulatory properties of our LPAs, we used a human em-
bryonic kidney 293 (HEK293) cell line deﬁcient in most TLRs,on of LPAs in the highest afﬁnities complexes with the crystal structure of triacylated C16
n of LPAswith the crystal structure of diacylatedC16 lipopeptide Cys-Ser-Lys4 (Pam2CSK4)
d protein structures or homology models. The ligands are represented in coloured sticks.
Fig. 8.Hydrogen bonds in LPA-TLR2 complexes aremainlymediated by the peptide chain instead of side chains. Polar contacts in the highest afﬁnity LPA complexes. (A) RPR 128506; (B)
RPR 120535; (C) RPR 120525. TLR2 residues involved in hydrogen bonds are shown in green and TLR1 in cyan.
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TLRs that recognize lipids, Toll-like receptors 2 or 4, by transient
transfection with their co-receptors CD14 or MD2 and CD14 re-
spectively. We observed NF-κB activation after incubation with li-
posomes in a dose-dependent manner when HEK293 cells were
transfected with hTLR2/CD14 (black bars), in contrast to cells
transfected with hTLR4/MD2/CD14 (grey bars) (Fig. 3A). As ex-
pected, no activation was detected after stimulation of hTLR2/
CD14 transfected cells with the TLR4 ligand, lipopolysaccharide
(LPS), whereas stimulation with the TLR2/TLR1 speciﬁc ligand,
the synthetic lipopeptide Pam3CSK4, and the TLR2/TLR6 speciﬁc li-
gand, Pam2CSK4 led to robust NF-κB activation. Similarly, hTLR4/
MD2/CD14 transfected cells responded only to LPS and not to
TLR2 ligands.
In order to investigate if LPAs are able to activate TLR2 even when
complexed to nucleic acids, we incubated TLR2-transfected cells with
lipoplexes formed by incubating RPR 120535, 120525 or 128506 with
siRNA and pDNA as described in the transfection protocol [56–61]. As
with the liposomes, lipoplexes activated NFκB when incubated with
TLR2/CD14-transfectedHEK293 cells. As expected these cells responded
only to Pam2CSK4 and not to TLR4 ligands (Fig. 3B).
Next we tested whether activation of TLR2 contributed signiﬁcantly
to TNF-α secretion induced by RPR lipoplexes. This was achieved by
pre-incubating primed THP-1 cells with antibodies that block hTLR2
or hTLR4 prior to stimulation with lipoplexes. The stimulatory effect of
lipoplexes, measured through TNF-α secretion in cell supernatants,
was totally inhibited by antibodies blocking TLR2 (Fig. 4), demonstrat-
ing the role of TLR2 activation in the immunostimulatory properties of
LPA lipoplexes. The absence of inhibition after pre-incubationwith anti-
bodies blocking TLR4 demonstrates that the effect observed with anti-
TLR2 is speciﬁc. Controls with LPS and Pam3CSK4 conﬁrmed that the an-
tibodies were effective and speciﬁc at the concentrations used.Table 2
Hydrogen bonds in TLR2-liganded complexes are mostly mediated by the peptide chain.
The table lists the number of hydrogen bonds with the main chain (ﬁrst number) and
the side chains (second number). n.d. stands for not determined.
*Pam2CSK4 is bound to mouse proteins. All other models involve human proteins.
TLR2/TLR1 TLR2/TLR6
Lipid chains binding
mode
Both chains in
TLR2
One chain in each
receptor
Both chains in
TLR2
RPR 120535 3/0 3/2 4/0
RPR 128506 5/1 2/1 1/0
RPR 120525 3/0 3/3 3/0
Pam2CSK4* n.d n.d 4/0
Pam3CSK4 n.d 2/2 n.d3.3. LPA-induced TNF-α secretion is mainly dependent on TLR2/TLR1
heterodimer
In order to identify which co-receptor is involved in TLR2 activation
by LPAs, we pre-incubated primed THP-1 cells with antibodies blocking
hTLR2, hTLR1 or hTLR6 before stimulation with LPA liposomes, the
TLR2/TLR1 speciﬁc ligand Pam3CSK4, or the TLR2/TLR6 speciﬁc ligand
Pam2CSK4. TNF-α secretion induced by LPAs was strongly inhibited by
antibodies that block TLR2 and TLR1 (Fig. 5), demonstrating the main
role of TLR2/TLR1 heterodimer in the immunostimulatory properties
of LPAs. Controls with Pam2CSK4 and Pam3CSK4 conﬁrmed that the an-
tibodies were effective and speciﬁc at the used concentrations.
3.4. RPR lipopolyamines bind TLR2 heterodimers with afﬁnities comparable
to lipopeptides
In order to better understand the mechanism of action of LPAs we
performed docking studies on TLR2 alone and in complex with TLR1
or TLR6. We compared their binding mode and strength to available
crystal structures. We found that RPR molecules bound with greater af-
ﬁnity to heterodimeric rather than to monomeric TLR2 in support of
their agonistic activity. For instance, RPR 120535 binds the inactive con-
formation of TLR2 with a binding energy of−27.6 kcal/mol and the ac-
tive conformations of TLR2 at−28.5 to−32.5 kcal/mol in complexes
with either TLR6 or TLR1, respectively (Table 1). Moreover all three
RPR molecules tested bound both TLR2/TLR1 and TLR2/TLR6 heterodi-
mers with binding energies around−30 kcal/mol.
In an attempt to rationalize these energy terms we also calculated
them for TLR2 ligands with known crystal structures. We used the
same protocol to compare directly the values obtained for the LPAs test-
ed with the lipopeptide ligands. Pam3CSK4 binds human TLR2/TLR1
with much higher afﬁnity at−35.4 kcal/mol. Pam2CSK4 bound mouse
TLR2/TLR6 at −25.2 kcal/mol. Hence, RPR 120535, RPR 120525 and
RPR 128506 seem to be able to bind TLR2 heterodimers as strongly as
lipopeptides characterized by crystallographic studies.
3.5. RPR lipopolyamines adopt docking poses reminiscent of lipopeptide
binding mode
Visualization of the docking poses of the RPR molecules revealed 3
types of binding modes for each lipid: (i) binding to TLR2/TLR1 with
one aliphatic chain in each TLR (Fig. 6 A-C); (ii) binding to TLR2/TLR1
with both chains in TLR2 (Fig. 6 D-F); (iii) binding to TLR2/TLR6 with
both chains in TLR2 (Fig. 6 G-I).
All poses show a degree of similarity to lipopeptides Pam2CSK4 and
Pam3CSK4 binding as suggested by their superposition (Fig. 7). LPAs oc-
cupy the hydrophobic pocket of TLR2 either partially or fully and form
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tures with residues from TLR2 leucine-rich repeat (LRR) 11 to 13 and
TLR1 or TLR6 region spanning LRR9 to 12 (Table 1, Supplemental Figs.
S1–S9). It is also remarkable that, as in the crystal structures, most hy-
drogen bonds are generated with the TLR peptide backbone (Fig. 8,
Table 2).
As with lipopeptide ligands, LPAs are able to occupy the TLR1 pocket
with one fully extended lipid chain while engaging partially the TLR2
pocket with their second chain (Fig. 7A). Indeed the bend conformation
within the hydrophobic TLR2 cavity allows an individual aliphatic chain
to ﬁll an otherwise much deeper pocket. This conformation is similar to
a cis double bond in an unsaturated chain between atoms C7 and C10.
Superposition of the docking poses shows that Pam3CSK4 projects car-
bon atoms 9 to 11 of its lipid chains deeper inside TLR2 compared to
the U-turn adopted by RPR molecules (Fig. 7A). Moreover this is not
the preferred binding mode of the more hydrophobic compound, RPR
128506, that favours a more buried conformation with both aliphatic
chains inside TLR2 (Fig. 6D). The preference of this compound for a
TLR1 instead of a TLR6 heterodimer will be discussed.
Overall it is striking how well the conserved amide-bound lipid
chains of all RPR molecules overlap with Pam3CSK4 in their TLR1 bind-
ing mode, whereas TLR2 binding seems to offer more ﬂexibility, both
at the level of their lipid tail and cationic headgroup positioning (Fig.
8). While all docking poses are shown in Supplemental Figs. S1–S9,
belowwewill only describe at an atomic level one docking pose to illus-
trate for each lipid the complex of highest afﬁnity. We use a standard
numbering for TLR2 residues whereas TLR1 amino acidswill be referred
to with an asterisk, TLR6 amino acids, with two asterisks and conserved
contacts compared to crystals are discussed.
3.6. RPR 120535 and 120525 bind preferentially TLR2/TLR1 with one lipid
chain per TLR
The highest afﬁnity complex is formed by linear RPR120535 and its
branched counterpart RPR 120525, which bound with energies of
−32.2 and −32.5 kcal/mol, respectively, with TLR2/TLR1 with one
lipid chain per TLR (Fig. 6 B–C, Table 1 and Supplemental Figs. S2 and
S3).
One lipid chain of RPR 120525makes hydrophobic interactionswith
TLR2 residues from LRR11 (Ile319, Leu324, Tyr326, Leu328), LRR12
(Val343, Lys347, Val348, Phe349, Leu350, Val351, Pro352, Leu355)
and LRR13 (Tyr376). TLR1 buries the other one using residues from
LRR9 (Trp258′), LRR11 (Ile304′, Val311′, Phe312′, Phe314′, Pro315′,
Ile319′, Tyr320′, Phe323′) and LRR12 (Thr336′, Arg337′, Met338′). The
polyamine headgroup makes hydrophilic interactions with TLR2 resi-
due Phe325 in LRR11 via the carbonyl group of its peptide chain,
which is a hydrogen acceptor of the secondary amine in position 4′.
TLR2 alsomakes unique side chain interactions, in particular an ionic in-
teraction between primary amine N15” and the carboxylate side chain
of Asp327, along with a hydrogen bond between the same amine,
Y326 and Ser329.
Crosslinking interactions are mediated between the polyamine
headgroup and the peptide chain of TLR1 at Gly313′ and Gln316′ from
LRR11. The interaction with Gly313′ occurs between its CO group (hy-
drogen bond acceptor) and the ligand′s secondary amine at N7′ (hydro-
gen bond donor) and is shared by Pam3CSK4 that binds in a similar
fashion. In contrast the contact mediated by Gln316′ differs between
the two ligands. While Gln316′mediates a side chain amine NE2 inter-
action in the Pam3CSK4 complex, here the interaction is mediated in-
stead by its main chain amino group as a hydrogen bond donor to the
ketone C_O in position 5′ of RPR 120525 (Fig. 8C).
According to our docking analysis RPR 120535 also binds preferen-
tially with its lipid chains spread across the TLR2/TLR1 heterodimer de-
spite its binding mode differing quite signiﬁcantly at the level of
hydrogen bonding (Fig. 8B). In contrast to its branched counterpart
this molecule is only a hydrogen bond donor with each amine groupinvolved. Its terminal amine N20′ gives a hydrogen bond to the OD1
side chain of TLR2 Asn294. Next secondary amine N20′ interacts with
the hydroxyl group of Ser329 and N15′ contacts TLR1 Gly313′ at the di-
meric interface. N11′ shares 2 hydrogen bondswith the peptide chain at
TLR2 Leu324 and Phe325 that also reaches out toN8′. Hydrophobic con-
tacts overlap well with the ones described previously and involve TLR2
LRR11 residues (Ile319, Phe322, Tyr326, Asp327, Thr330), LRR12
(Val343, Lys347, Val348, Phe349, Leu350, Val351, Leu355) and LRR13
residues (Leu359, Leu365, Leu367, Tyr376); and TLR1 LRR9 residue
(Phe261′), LRR11 (Ile304′, Val307′, Phe312′, Phe314′, Pro315′,
Gln316′, Ile319′, Tyr320′) and LRR12 (Thr336′, Arg337′).
3.7. RPR 128506 binds preferentially TLR2/TLR1 with both chains in TLR2
RPR 128506docks best to TLR2/TLR1 by inserting both lipid chains in
TLR2 instead of one chain per TLR (Fig. 6 D, Table 1 and supplemental
S4). This compound is similar to RPR 120535 in structure with its linear
head group but contains a linker of an additional four carbons between
its amide groups, which seems to improve its binding to TLR2within the
TLR2/TLR1 heterodimer compared to RPR 120535. The hydrophobic
spacer may also deter binding of one chain per TLR due to its entropic
contribution and adverse solvent exposure.
In the TLR2/TLR1 complex with both chains occupying TLR2, hydro-
phobic interactions are mediated by TLR2 LRR9 (Ile261, Leu266), LRR10
(Phe284, Leu289, Phe295), LRR11 (Pro306, Leu312, Ile314, Leu317,
Ile319, Tyr326, Asp327, Leu328, Leu331), LRR12 (Leu334, Thr335,
Val338, Ile341, Val343, Ser346, Val348) and LRR13 (Leu359, Leu367)
and remarkably few TLR1 residues in LRR11 (Phe312′, Gly313′,
Pro315′). Two hydrogen bonds are formed with the TLR1 main chain
carbonyl group at Phe312′ and the side chain of Gln316′, which is con-
served in Pam3CSK4 binding (Fig. 8A). Another four hydrogen bonds
occur with the peptide chain of TLR2 at Leu324, Phe325, Phe349 and
Leu350 (LRR11–12) with the CO group of the ﬁrst two residues and
the NH group of the latter two. In the best docking poses the ligand is
buried 2.5 Å deeper inside the hydrophobic TLR2 pocket in the TLR1-
heterodimer compared to the TLR6 one. This results in an increase in hy-
drophobic contacts and a decrease of conserved hydrophilic interac-
tions of the headgroup. Indeed none of the usual residues involved in
hydrogen bonding are found in the TLR2/TLR6 heterodimer (TLR2 resi-
dues Leu324 and Tyr326; TLR1 residues Ser320′, Thr322′ and Tyr323′),
which would suggest a novel bindingmechanism based on the promis-
cuous accommodation of the polar head for a ligand with an increased
hydrophobic contribution (Table1 and supplemental Figs. S7).
3.8. Molecular reason for the TLR2/TLR1 preference over TLR2/TLR6 by LPAs
Overall, despite LPAs possessing two alkane chains, these molecules
performed best on TLR2/TLR1 heterodimers in our docking analysis. In
order to determine the molecular reason for this preference we looked
into the atomic details of RPR 120525, which was the strongest TLR2/
TLR6 ligand among the set of LPAs tested at−31.7 kcal/mol.
In the TLR2/TLR6 complex hydrophobic interactions are mainly me-
diated by TLR2 residues in LRR9 (Ile261), LRR10 (Phe284, Asn294,
Phe295, Arg296), LRR11 (Ile314, Leu317, Ile319, Tyr326, Asp327,
Leu328, Ser329, Thr330, Leu331), LRR12 (Ile341, Val343, Ser346,
Lys347, Val348, Phe349, Leu350, Val351, Pro352, Leu355) and LRR13
(Leu359, Leu365, Leu367). TLR6 Leu318” and Phe319” contribute to hy-
drophobic interactions. The former is also a hydrogen bond acceptor via
its peptide bond for a primary amine side chain of the LPA. Further hy-
drogen bonding involves TLR2 residues at Gly293 and Phe325 equally
mediated by their main chain CO group. While each ligand has slightly
different contacts with the receptor complex, branched RPR 120525
shares more features with Pam2CSK4 than the other two LPAs (Fig. 7B,
Table 1). The atoms that link the lipid chains in both molecules are
only 1.0 Å apart with both the headgroups and the lipid chains occupy
the same overall space. In contrast, when we compare RPR 120525 in
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headgroup is shifted upwards by 5.1 Å upon TLR1 interaction. Hence
the TLR6 complex conformation may appear more compact compared
to the TLR1 with increased TLR2 hydrophobic interactions while pre-
serving a single hydrophilic contact at the dimer interface with TLR6.
Given that the TLR1 heterodimer mediates twice as many hydrogen
bonds compared to TLR6, the docking algorithm used in this study pre-
dicts a higher afﬁnity for the latter (Table 1).
4. Discussion
To date TNF-α secretion observed after stimulation of cells with
lipoplex has been attributed to activation of TLR3, TLR7, TLR8 and TLR9
by nucleic acids, whereas cationic lipids were considered as inert for the
immune system [22,23,35]. We presently show instead that the RPR
120525, 120535 and 128506 lipoplexes possess immunostimulatory
properties conserved in the absence of cargo nucleic acids, and that di-
C18 lipopolyamines RPR 120525, 120535 and 128506 were all able to in-
duce TNF-α secretion through a mechanism strictly dependent on TLR2.
It has been shown that the length of the aliphatic hydrocarbon
chains between C12 and C18 in cationic lipids determines their transfec-
tion efﬁciency. The conﬁguration of their linker andhead group is equal-
ly important; cationic lipids whose aliphatic chains are linked to
polyamines by an amide linker show the best transfection efﬁciency
[51,52,54,59,73,74].
For these reasons, syntheses of transfection agents have produced,
and continue to produce, cationic lipids sharing many features with
the LPAs here investigated (the amide linker, the carbonyl and amino
groups and the saturated carbon chains) [53,57,60,75–81].
TLR2 senses a wide range of ligands that includes bacterial
lipopeptides and lipoglycans among others [34]. Synthetic LPAs,
engineered to deliver nucleic acids to cells, are chemically distinct
from typical TLR2 ligands but share these features with lipopeptides.
Molecular docking shows that the alkyl chains of lipopolyamines are
shielded from the solvent in a hydrophobic pocket upon TLR2 binding,
which was shown to be large enough to accommodate up to 18 carbon
atoms [65,82]. The hydrophilic head imitates carboxyl and amino
groups of lipopeptide backbone, which rather than side chains mediate
H-bond with TLR residues [65,82]. Overall, each lipopolyamine forms
conserved and new H-bonds, most of which, as in crystals, are with
the TLR peptide chains; this lack of speciﬁcity is potentially critical for
mediating promiscuity in TLR2-ligand sensing.
Thus these features which enhance transfection efﬁciency also con-
fer immunostimulatory properties to these cationic lipid nanocarriers
by mimicking TLR2 ligands. Our results are in agreement with TLR2-
lipopeptides structural activity relationships reported by Buwitt-
Beckmann [83], Spohn [84], Okusawa [85] and Morr [86], which show
that human TLR2 is able to recognize a large variety of synthetic
lipopeptide structures, which can differ in terms of chain length (from
C12 to C18), peptide sequence and number of amino acids (conﬁrming
the promiscuity of the hydrogen bonds). Spohn et al. also showed that
lipopeptides in which the S atom of the acrylate cysteine is replaced
by a C atom are still able to activate TLR2 but with a reduced biological
activity [84]. This substitution is also found in lipopolyamines, andmost
likely contributes to the weaker maximal activity of RPR compounds
compared to lipopeptides (Supplemental Fig. S10).
In agreement with our results, with the aim to confer to a TLR2 li-
gand a carrier property, InvivoGen replaced the peptide head of
lipopeptide Pam2CSK4 with a polyamine (spermine) and this modiﬁca-
tion conferred delivery properties without losing TLR2 activation [87].
Here we show that it is due to the promiscuity of H-bond formation,
and that TLR2 activation is retained not only when the polar head is re-
placed by polyamines, but also acyl chains and cysteine linker of
lipopeptides by simple alkyl chains.
The di-C14 RPR206252was so far the only cationic lipid shown to ac-
tivate Toll-like receptor 2 and only in the absence of nucleic acids [45].Our work illustrates that the TLR2-dependent immunostimulatory
properties previously shown for this lipopolyamine are shared by a set
of longer LPAs up to di-C18.
Our results suggest that all saturated LPAs may activate TLR2. This
could explain the LPA-lipoplex dependent inﬂammatory responses ob-
served in lipoplexes deﬁcient in nucleic acid-TLR recognition [40–44].
However the immune response is dose dependent and is lower when
LPAs are in lipoplex form. Furthermore, the response can vary depend-
ing on the cell lines or in vivo substrates used. We recommend testing
the inﬂammatory properties of a lipoplex in the conditions used for
transfections in order to evaluate its safety.
4.1. A hydrophobic tail tale
The two aliphatic chains in LPAs fully occupy the TLR2 lipid-binding
pocket and could therefore constitute ideal TLR2/TLR6 ligands. LPAs also
share the amide linkage of the third lipid chain of the prototypical
lipopeptide Pam3CSK4. TLR2/TLR1 complexes bound to LPA either dis-
play an empty TLR1 pocket and a fully ﬁlled TLR2 cavity, or a TLR1 pock-
et ﬁlled with one aliphatic chain and a TLR2 cavity partially ﬁlled with
one kinked chain which mimicks the binding of two chain. Both cases
are entropically unfavourable, whichmight explain the reduced efﬁcacy
and potency of LPAs compared to lipopeptides (Supplemental Fig. S10).
Together with the biological data obtained by blocking TLR1 or TLR6
on human macrophages, the apparent afﬁnities of RPR molecules for
TLR2 suggest that LPAs bind preferentially to TLR2/TLR1 but do not
rule out TLR6 as a heterodimerization partner of TLR2 in lipopolyamine
signalling.
The participation of TLR6 in dimer formation could occur in other
cells or conditions, perhaps in the absence of TLR1. Indeed Pam2CSK4,
speciﬁc of TLR2/TLR1 heterodimer, has been shown to activate TLR2/
TLR6 in knock-out mice or SW620 cells transfected with TLR2 and
TLR6 suggesting partially overlapping binding capacities of both types
of heterodimers [83,88].
In the absence of crystallographic data, the actual conformation of an
“empty” TLR1 is unknown, in contrast to TLR2, which undergoes struc-
tural rearrangements within its lipid binding region located in leucine-
rich repeat LRR10–11 [82]. Finally the apparent ligand afﬁnities that we
calculated for TLR2/TLR1 and TLR2/TLR6 complexes do not take into ac-
count the compensatory interactions made by TLR6 that increases its
protein-protein contacts at the dimer interface. In contrast TLR1 relies
on the ligand to crosslink the heterodimer. A molecular collaboration
between LPAs within a given TLR2 dimer, whether it is with TLR1 or
TLR6, might govern the ﬁnal positioning of the ligand, thus embracing
the potential existence of both types of heterodimeric complexes.
Interestingly, in the conﬁguration that RPR bind TLR2/TLR1 hetero-
dimers by crosslinking them with one lipid chain per TLR, it is striking
how well the amide bound lipid buried in TLR1 overlays with the one
linked to the N-terminal cysteine found in Pam3CSK4. The overall con-
formation is more surface exposed compared to exclusively TLR2
bound lipids. A parallel can be drawn with the recognition of
underacylated lipopolysaccharide (LPS), lipid IVa, known to trigger acti-
vation of mouse TLR4 but not of human TLR4 [89–93]
In the human complex the ligand is completely buried inside the hy-
drophobic pocket of MD-2. In the mouse complex, the negatively
charged phosphates of the lipid IVa head group contact species-speciﬁc
positively charged TLR4 residues, which promote an alternative more
surface exposed orientation of the ligand [93]. This in turn allows lipid
IVa to occupy nearly the same space as LPS, although it lacks two sec-
ondary acyl chains. Thus, insufﬁcient hydrophobic interactions by an
underacylated ligand can be compensated for by additional polar con-
tacts mediated by the head group. We propose that this principle may
also apply to TLR2/TLR1 heterodimers, and propose that diC18 LPAs
can activate it with only one aliphatic chain per TLR.
The alkane chainwithin the TLR2 pocket adopts a U-turn from about
C4 up to C10 depending on the lipopolyamine. The critical hydrophobic
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stead of two extended lipid chains thanks to amolecular kink, which oc-
cupies the space of two C6 chains approximately. However, separately 2
hexyl chains do not trigger TLR2 activity as described by Buwitt-
Beckmann et al. who characterized the TLR2 activity of a PamHex2
lipopeptide [83]. We postulate that the single C18 chain bends in such
a manner to block off the entrance of the TLR2 pocket, which seems to
generate sufﬁcient steric constraint to activate TLR2. The conﬁguration
obtained in the docking pose would be best captured using a cis double
bond derivative within one of the alkane chains involving a couple of
adjacent carbon atoms located somewhere between C4 and C10. Pre-
liminary results with a new lipopolyamine RPR 208484 that carries
one saturated C18 chain and one unsaturated C18:1, Δ9 chain displays
the same immune-stimulatory activity as its parent molecule, the fully
saturated RPR 120535 (Supplemental Fig. S11), which strongly supports
the proposed binding model.
Lipoteichoic acids (LTAs) have been reported to either activate TLR2/
TLR1 or TLR2/TLR6 heterodimers [94–96].
Remarkably, Streptococcus pneumonia LTA carries a cis double bond
C16:1, Δ9 in only one of its palmitate chain. It is still recognized by
TLR2, and activates TLR2/TLR1 althoughwith lower efﬁciency compared
to unsaturated LTA from Staphylococcus aureus [95]. In turn, saturated
Staphylococcus aureus LTA preferentially activates TLR2/TLR6 in a more
shielded binding mode that can be enhanced by the cooperative
crosslinking of hydrophilic mannose binding lectins [94]. Our LPAs
and in particular the branched RPR 120525 which buries itself deeper
into the TLR2/TLR6 complex compared to TLR2/TLR1, therefore also
compare well with the activity of natural TLR2 ligands.
Moreover given the size of the TLR2 and TLR1 lipid pockets we pre-
dict that it is inconceivable for two unsaturated chains to be bound by
TLR2 complexes of any kind. This in turn is supported by the total lack
of NF-κB dependent immunostimulatory activity of DOSPA component
of lipofectamine transfection reagents that carries two unsaturated
chains [35,97] (Supplemental Fig. S12) even though the lack of the
ether-dimethylamine linkage, which could result in a loss of H-bonds,
can't be excluded as a cause. Taken together there is growing evidence
for a TLR2/TLR1 binding mode of di-C18 lipopolyamines as well as un-
saturated lipoglycans and di-acyl lipopeptides that sequesters one
lipid chain in each TLR.
4.2. Head group-receptor speciﬁcity and TLR2 promiscuity
In terms of innate immune response our study shows that the con-
ﬁguration of the head group of lipopolyamines imparts some degree
of TLR2 speciﬁcity.
The narrow channel at the dimerization interface requires the li-
gands to remain linear over a distance of at least 6 Å. While aliphatic
chains can be accommodated in non-speciﬁc ways in hydrophobic
pockets, the precise positioning of the head group regulates TLR2 signal-
ling as it can interfere with the dimerization process [82]. Moreover the
fact that TLR2 possesses a range of non-lipidic ligands (for instance
hyaluronic acid, teichoic acid, and zymosan) also supports the function-
al importance of the solvent-exposed moiety of the ligand. In other
words the interaction of their hydrophilic part is equally critical for
TLR2 activation and may differ from lipopeptides. Unfortunately there
is no crystal structure to date to describe their respective binding
modes.
Recently, some insight was provided by the structure of the TLR2
ectodomain solved in the absence of added ligand [98]. Interestingly
the TLR2 hydrophobic pocketwas ﬁlledwith a plasmamembrane phos-
pholipid, most likely a phosphatidylcholine (PC). It bound between
LRR11 and 12 in the same position as inactive ligands previously charac-
terized [82]. The structure was also solved in the presence of staphylo-
coccal superantigen-like protein 3 (SSL3), a secreted protein that is a
potent TLR2 inhibitor. It was shown that SSL3 prevents TLR2 signalling
in two ways. The presence of SSL3 prevents ligand binding to TLR2 bypartially obstructing the entrance of the lipid-binding pocket. More im-
portantly, the presence of Pam2CSK4 already bound to TLR2 does not
prevent SSL3 binding which in turn prevents the recruitment of TLR6.
Using docking analysis, it was then shown that the binding mode of
Pam2CSK4 had to differ signiﬁcantly from theone observed in the crystal
structure of the TLR2/TLR6 complex in order to be compatible with SSL3
binding. This is achieved by the ligand adopting alternative head group
interactions with TLR2.
If the ligand itself does not determine its bindingmode to TLR2, then
this necessarily means that activation is a cooperative mechanism,
which includes the TLR2 dimerization partner. In other words TLR2 is
not enough to fully engage the ligand. Cooperativity and promiscuity
might also be responsible for the heterogeneity of the LPA binding
poses predicted here. Further studies will be necessary to conﬁrm that
diC18 have indeed such a broad binding spectrum.
5. Conclusion
Tested LPAs activate the innate system via TLR2 whether they are
delivered in liposome or lipoplex forms. Docking predicts binding
poses suitable for either TLR1 or TLR6-driven heterodimerization,
while binding energies and biological data seem to favour the former.
We determined the structural parameters responsible for TLR2 recogni-
tion, extending our results from three very speciﬁc lipids to a large num-
ber of molecules currently commercialized or proposed to be used as
transfection agents. These parameters are most likely to be chosen in
the future synthesis of transfection agents because they confer ease of
synthesis, while combining biocompatibility and efﬁciency of transfec-
tion. Therefore our study emphasizes the importance of assessing the
inﬂammatory properties of lipoplexes to estimate the safety of transfec-
tion, and also aims atwarning and guiding on planning new synthesis of
non-immunostimulatory nanocarriers. We propose docking analysis as
a preliminary screening tool to evaluate pathogen recognition receptor
binding for those receptors with available crystal structures. For in-
stance, we predicted that TLR2 activation could no longer be achieved
if both LPA chains were unsaturated. Upon biological test, such com-
pounds would provide new non-immunogenic lipoplexes suitable for
gene therapy. However, the immunostimulatory properties of saturated
LPAsmight also be of interest for the development of vaccine adjuvants,
especially considering the non-toxicity of LPAs.
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